companiesCompany
Menarini / Stemline
Menarini is the private Italian pharma that commercialises the first oral SERD, elacestrant.
Elacestrant (Orserdu), tagraxofusp (Elzonris).
ApprovedOral SERD
Elacestrant · Orserdu
Elacestrant was the first oral oestrogen-receptor degrader (2023), for ESR1-mutant breast cancer detected by blood test.
ApprovedRecombinant cytotoxin (IL-3 fused to diphtheria toxin)
Tagraxofusp · Elzonris
Tagraxofusp is a fusion of the growth factor IL-3 with a bacterial toxin that homes to CD123 on a rare, aggressive blood cancer.